Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001140361-18-009665

Options or other derivatives

  • Interim CEO acquired 178,400 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Quinn Anthony G. · Interim CEO

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2018-02-20 Grant or award : show line 1 in the form Employee Stock Option (right to buy) +178,400 178,400 D
Loading xslF345X03/doc1.xml…